Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients

Atsunori Yorozu, Nobuko Kuroiwa, Akane Takahashi, Kazuhito Toya, Shiro Saito, Toru Nishiyama, Yasuto Yagi, Tomoaki Tanaka, Yutaka Shiraishi, Toshio Ohashi

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Purpose: To report outcomes for men treated with iodine-125 (125I) prostate brachytherapy (BT) at a single institution in Japan. Methods and Materials: Between 2003 and 2009, 1313 patients (median age, 68years) with clinically localized prostate cancer were treated with 125I BT. Median prostate-specific antigen level was 7.6ng/mL (range, 1.1-43.3). T-stage was T1c in 60%, T2 in 39%, and T3 in 1% of patients. The Gleason score was <7, 7, and >7 in 49%, 45%, and 6% of patients, respectively. Neoadjuvant androgen deprivation therapy was used in 40% of patients and combined external beam radiotherapy of 45Gy in 48% of patients. Postimplant dosimetry was performed after 30days after implantation, with total doses converted to the biologically effective dose. Survival functions were calculated by the Kaplan-Meier method and Cox hazard model. Results: Median followup was 67months (range, 6-126). The 7-year biochemical freedom from failure for low-, intermediate-, and selected high-risk prostate cancers were 98%, 93%, and 81%, respectively (. p<0.001). Multivariate analysis identified the Gleason score, initial prostate-specific antigen level, positive biopsy rate, dose, and neoadjuvant androgen deprivation therapy as predictors for biochemical freedom from failure. The 7-year actuarial developing Grade 3+ genitourinary and gastrointestinal toxicity was 2% and 0.3%, respectively. Forty-four percent patients with normal baseline potency retained normal erectile function at 5years. Conclusions: 125I prostate BT is a highly effective treatment option for low-, intermediate-, and selected high-risk prostate cancers. Side effects were tolerable. An adequate dose may be required to achieve successful biochemical control.

Original languageEnglish
Pages (from-to)111-117
Number of pages7
JournalBrachytherapy
Volume14
Issue number2
DOIs
Publication statusPublished - 2015 Mar 1

Fingerprint

Brachytherapy
Prostate
Japan
Radiotherapy
Prostatic Neoplasms
Neoplasm Grading
Prostate-Specific Antigen
Proportional Hazards Models
Androgens
Iodine
Therapeutics
Multivariate Analysis
Biopsy
Survival

Keywords

  • Brachytherapy
  • Dose-response
  • Iodine-125
  • Low-dose-rate
  • Permanent seed implantation
  • Prostate cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan : Outcomes of 1300 patients. / Yorozu, Atsunori; Kuroiwa, Nobuko; Takahashi, Akane; Toya, Kazuhito; Saito, Shiro; Nishiyama, Toru; Yagi, Yasuto; Tanaka, Tomoaki; Shiraishi, Yutaka; Ohashi, Toshio.

In: Brachytherapy, Vol. 14, No. 2, 01.03.2015, p. 111-117.

Research output: Contribution to journalArticle

Yorozu, Atsunori ; Kuroiwa, Nobuko ; Takahashi, Akane ; Toya, Kazuhito ; Saito, Shiro ; Nishiyama, Toru ; Yagi, Yasuto ; Tanaka, Tomoaki ; Shiraishi, Yutaka ; Ohashi, Toshio. / Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan : Outcomes of 1300 patients. In: Brachytherapy. 2015 ; Vol. 14, No. 2. pp. 111-117.
@article{21ab1e745ecd455f9355723d5bf64926,
title = "Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan: Outcomes of 1300 patients",
abstract = "Purpose: To report outcomes for men treated with iodine-125 (125I) prostate brachytherapy (BT) at a single institution in Japan. Methods and Materials: Between 2003 and 2009, 1313 patients (median age, 68years) with clinically localized prostate cancer were treated with 125I BT. Median prostate-specific antigen level was 7.6ng/mL (range, 1.1-43.3). T-stage was T1c in 60{\%}, T2 in 39{\%}, and T3 in 1{\%} of patients. The Gleason score was <7, 7, and >7 in 49{\%}, 45{\%}, and 6{\%} of patients, respectively. Neoadjuvant androgen deprivation therapy was used in 40{\%} of patients and combined external beam radiotherapy of 45Gy in 48{\%} of patients. Postimplant dosimetry was performed after 30days after implantation, with total doses converted to the biologically effective dose. Survival functions were calculated by the Kaplan-Meier method and Cox hazard model. Results: Median followup was 67months (range, 6-126). The 7-year biochemical freedom from failure for low-, intermediate-, and selected high-risk prostate cancers were 98{\%}, 93{\%}, and 81{\%}, respectively (. p<0.001). Multivariate analysis identified the Gleason score, initial prostate-specific antigen level, positive biopsy rate, dose, and neoadjuvant androgen deprivation therapy as predictors for biochemical freedom from failure. The 7-year actuarial developing Grade 3+ genitourinary and gastrointestinal toxicity was 2{\%} and 0.3{\%}, respectively. Forty-four percent patients with normal baseline potency retained normal erectile function at 5years. Conclusions: 125I prostate BT is a highly effective treatment option for low-, intermediate-, and selected high-risk prostate cancers. Side effects were tolerable. An adequate dose may be required to achieve successful biochemical control.",
keywords = "Brachytherapy, Dose-response, Iodine-125, Low-dose-rate, Permanent seed implantation, Prostate cancer, Radiotherapy",
author = "Atsunori Yorozu and Nobuko Kuroiwa and Akane Takahashi and Kazuhito Toya and Shiro Saito and Toru Nishiyama and Yasuto Yagi and Tomoaki Tanaka and Yutaka Shiraishi and Toshio Ohashi",
year = "2015",
month = "3",
day = "1",
doi = "10.1016/j.brachy.2014.06.008",
language = "English",
volume = "14",
pages = "111--117",
journal = "Brachytherapy",
issn = "1538-4721",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Permanent prostate brachytherapy with or without supplemental external beam radiotherapy as practiced in Japan

T2 - Outcomes of 1300 patients

AU - Yorozu, Atsunori

AU - Kuroiwa, Nobuko

AU - Takahashi, Akane

AU - Toya, Kazuhito

AU - Saito, Shiro

AU - Nishiyama, Toru

AU - Yagi, Yasuto

AU - Tanaka, Tomoaki

AU - Shiraishi, Yutaka

AU - Ohashi, Toshio

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Purpose: To report outcomes for men treated with iodine-125 (125I) prostate brachytherapy (BT) at a single institution in Japan. Methods and Materials: Between 2003 and 2009, 1313 patients (median age, 68years) with clinically localized prostate cancer were treated with 125I BT. Median prostate-specific antigen level was 7.6ng/mL (range, 1.1-43.3). T-stage was T1c in 60%, T2 in 39%, and T3 in 1% of patients. The Gleason score was <7, 7, and >7 in 49%, 45%, and 6% of patients, respectively. Neoadjuvant androgen deprivation therapy was used in 40% of patients and combined external beam radiotherapy of 45Gy in 48% of patients. Postimplant dosimetry was performed after 30days after implantation, with total doses converted to the biologically effective dose. Survival functions were calculated by the Kaplan-Meier method and Cox hazard model. Results: Median followup was 67months (range, 6-126). The 7-year biochemical freedom from failure for low-, intermediate-, and selected high-risk prostate cancers were 98%, 93%, and 81%, respectively (. p<0.001). Multivariate analysis identified the Gleason score, initial prostate-specific antigen level, positive biopsy rate, dose, and neoadjuvant androgen deprivation therapy as predictors for biochemical freedom from failure. The 7-year actuarial developing Grade 3+ genitourinary and gastrointestinal toxicity was 2% and 0.3%, respectively. Forty-four percent patients with normal baseline potency retained normal erectile function at 5years. Conclusions: 125I prostate BT is a highly effective treatment option for low-, intermediate-, and selected high-risk prostate cancers. Side effects were tolerable. An adequate dose may be required to achieve successful biochemical control.

AB - Purpose: To report outcomes for men treated with iodine-125 (125I) prostate brachytherapy (BT) at a single institution in Japan. Methods and Materials: Between 2003 and 2009, 1313 patients (median age, 68years) with clinically localized prostate cancer were treated with 125I BT. Median prostate-specific antigen level was 7.6ng/mL (range, 1.1-43.3). T-stage was T1c in 60%, T2 in 39%, and T3 in 1% of patients. The Gleason score was <7, 7, and >7 in 49%, 45%, and 6% of patients, respectively. Neoadjuvant androgen deprivation therapy was used in 40% of patients and combined external beam radiotherapy of 45Gy in 48% of patients. Postimplant dosimetry was performed after 30days after implantation, with total doses converted to the biologically effective dose. Survival functions were calculated by the Kaplan-Meier method and Cox hazard model. Results: Median followup was 67months (range, 6-126). The 7-year biochemical freedom from failure for low-, intermediate-, and selected high-risk prostate cancers were 98%, 93%, and 81%, respectively (. p<0.001). Multivariate analysis identified the Gleason score, initial prostate-specific antigen level, positive biopsy rate, dose, and neoadjuvant androgen deprivation therapy as predictors for biochemical freedom from failure. The 7-year actuarial developing Grade 3+ genitourinary and gastrointestinal toxicity was 2% and 0.3%, respectively. Forty-four percent patients with normal baseline potency retained normal erectile function at 5years. Conclusions: 125I prostate BT is a highly effective treatment option for low-, intermediate-, and selected high-risk prostate cancers. Side effects were tolerable. An adequate dose may be required to achieve successful biochemical control.

KW - Brachytherapy

KW - Dose-response

KW - Iodine-125

KW - Low-dose-rate

KW - Permanent seed implantation

KW - Prostate cancer

KW - Radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=84924073439&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924073439&partnerID=8YFLogxK

U2 - 10.1016/j.brachy.2014.06.008

DO - 10.1016/j.brachy.2014.06.008

M3 - Article

C2 - 25127123

AN - SCOPUS:84924073439

VL - 14

SP - 111

EP - 117

JO - Brachytherapy

JF - Brachytherapy

SN - 1538-4721

IS - 2

ER -